RARG
ENSG00000172819
Target class
Nuclear receptor
Chromosome
12
Approved drugs
9
Clinical candidates (approved and in development)
11
- Approved drugs
- 9
- Clinical candidates (approved and in development)
- 11
- Chemical probe available
- Yes
- Target name
- RARG
- Gene name
- Retinoic acid receptor gamma
- Gene symbol
- RARG
- Protein name
- Retinoic acid receptor gamma (RAR-gamma) (Nuclear receptor subfamily 1 group B member 3)
- RARC
- NR1B3
- RARgamma
- RAR-gamma
- Gene biotype
- Protein coding
- Gene family
- Retinoic acid receptors
- Target class
- Nuclear receptor
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 135.86
- Tissue specificity (Gini)
- 0.553
- Tissue specificity (tau)
- 0.825
- KEGG gene identifiers
- hsa:5916
- Protein interaction confidence
- 0.858308
- Protein interaction partners
- 13
- R-HSA-383280
- R-HSA-5362517
- R-HSA-5617472
- End position
- 53232980
- Start position
- 53210566
- Chromosome
- 12
- Strand
- Reverse
- Nucleus . Cytoplasm .
- Nucleoplasm
Publication evidence
- PubMed 28167758
- Tissue specificity (tau)
- 0.824949
- Expression inequality (Gini)
- 0.553266
Expression in transcripts per million
- Esophagus - Mucosa
- 135.86
- Skin - Sun Exposed (Lower leg)
- 130.75
- Skin - Not Sun Exposed (Suprapubic)
- 114.84
- Vagina
- 94.27
- Cervix - Endocervix
- 62.54
Expression in transcripts per million
- Esophagus - Mucosa135.86
- Skin - Sun Exposed (Lower leg)130.75
- Skin - Not Sun Exposed (Suprapubic)114.84
- Vagina94.27
- Cervix - Endocervix62.54
- Cervix - Ectocervix61.97
- Cells - Cultured fibroblasts47.84
- Nerve - Tibial47.66
- Uterus42.36
- Fallopian Tube38.56
- Thyroid36.44
- Prostate35.88
- Artery - Aorta35.4
- Bladder32.15
- Artery - Tibial31.14
- Artery - Coronary30.05
- Ovary29.31
- Esophagus - Gastroesophageal Junction26.37
- Colon - Sigmoid26.14
- Minor Salivary Gland26.05
- Breast - Mammary Tissue25.32
- Esophagus - Muscularis22.17
- Lung20.58
- Brain - Cerebellum20.45
- Brain - Cerebellar Hemisphere18.37
And 29 more, listed on the interactive page.
- GO:0008361
- GO:0032526
- GO:0048384
- GO:0060070
- GO:0000785
- GO:0005634
- GO:0005654
- GO:0005737
- GO:0005515
- GO:1990837
regulation of transcription factor activity
- cell-based: ATG_DR5_RAR_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.
- cell-based: ATG_RARg_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.
- cell-based: ATG_DR5_RAR_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.
- cell-based: ATG_RARg_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.
Biological samples
- HepG2, cell line
Evidence source
Related records
Trials (572)
- "A Comparative Clinical Evaluation of the Efficacy of Topical Adapalene, Benzoyl Peroxide Gel, Oral Lactobacillus Rhamnosus, D-chiro-inositol, Inulin Capsule, and Their Fixed Combination in Mild to Moderate Acne Vulgaris Patients."
- "AIDA" Protocol (LAP 0493)
- 13-cis Retinoic Acid (Isotretinoin) and Sperm Production
- 13-Cis Retinoic Acid With or Without Vitamin E for Prevention of Lung Cancer
- 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma
- 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma
- 90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)
- A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema
- A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris
- A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris
- A Clinical Study Evaluating the Efficacy and Safety of Retinoic Acid in Patients With 15q11-q13 Duplication Syndrome
- A Clinical Study on the Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen in the Treatment of Intermediate-to-high-risk Rhabdomyosarcoma
- A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel
- A Companion Treatment Study for Patients With Moderate to Severe Acne Vulgaris
- A Comparative Study of Adapalene Gel,0.3% Versus Tretinoin Emollient Cream, 0.05% for the Treatment of Photoaging
- A Comparative Study of the Tolerability of Two Combination Therapies for the Treatment of Acne
- A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis
- A Phase 3 Study to Compare the Safety and Efficacy of 5% Dapsone Topical Gel, (DTG) Twice Daily in Combination With Once Daily Vehicle Control, Adapalene Gel 0.1% or Benzoyl Peroxide Gel 4%
- A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (301)
- A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (302)
Drugs (11)
- Acitretin Retinoid receptor agonist
- Adapalene Retinoic acid receptor agonist
- Alitretinoin Retinoid receptor agonist
- Etretinate Retinoid receptor agonist
- IRX4310 Retinoic acid receptor antagonist
- Isotretinoin Retinoic acid receptor agonist
- Mofarotene Retinoid receptor modulator
- Palovarotene Retinoic acid receptor gamma agonist
- Tazarotene Retinoic acid receptor agonist
- Tretinoin Retinoic acid receptor agonist
- Trifarotene Retinoic acid receptor gamma agonist